Irinotecan Hydrochloride Injection, Solution
Product Images NDC 61703-349

12 FDA label images from Hospira, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Irinotecan Hydrochloride (NDC 61703-349). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Irinotecan 01)

Chemical Structure (Irinotecan 01)
Chemical structure of Irinotecan Hydrochloride showing its molecular components including the piperidine rings, lactone moiety, and hydrochloride with three water molecules of hydration (3 H2O) indicated.*
FDA Label Image

Figure 1 (Irinotecan 02)

Figure 1 (Irinotecan 02)
A survival curve graph titled 'First-Line Irinotecan/5-FU/LV Vs 5-FU/LV Study 1.' The y-axis shows probability from 0.0 to 1.0, and the x-axis shows months from 0 to 42. Two survival lines are displayed, one for Irinotecan/5-FU/LV and one for 5-FU/LV, with a p-value of less than 0.05 indicated by a log-rank test.*
FDA Label Image

Figure 2 (Irinotecan 03)

Figure 2 (Irinotecan 03)
A line graph comparing survival probability over 30 months for two treatment groups: Irinotecan/5-FU/LV and 5-FU/LV. The vertical axis shows survival probability from 0 to 1.0, and the horizontal axis represents time in months. The Irinotecan/5-FU/LV group shows a higher survival probability over time compared to 5-FU/LV, with statistical significance noted (p<0.05).*
FDA Label Image

Figure 3 (Irinotecan 04)

Figure 3 (Irinotecan 04)
A Kaplan-Meier survival curve comparing the probability of survival over 21 months between Irinotecan and Best Supportive Care (BSC). The graph shows higher survival probability for Irinotecan with median follow-up and median survival times listed. The p-value from the log-rank test is 0.0001, indicating statistical significance.*
FDA Label Image

Figure 4 (Irinotecan 05)

Figure 4 (Irinotecan 05)
A Kaplan-Meier survival probability plot comparing Irinotecan and 5-FU over months. The x-axis represents time in months, ranging from 0 to 21, and the y-axis shows survival probability from 0 to 1. The graph includes median follow-up times and a p-value from a log-rank test assessing statistical significance.*
FDA Label Image

Hospira Logo (Irinotecan 06)

FDA Label Image

Principal Display Panel (2 mL Vial Label)

Principal Display Panel (2 mL Vial Label)
Label for Irinotecan Hydrochloride Injection, USP, 40 mg per 2 mL (20 mg/mL) intravenous solution in a 2 mL vial. The label notes the product is sterile, Rx only, for IV use only, and must be diluted before use. It is a cytotoxic agent distributed by Hospira, Inc. with storage and handling instructions, lot and expiration date fields, and barcode visible.*
FDA Label Image

Principal Display Panel (2 mL Vial Carton)

Principal Display Panel (2 mL Vial Carton)
The packaging label for Irinotecan Hydrochloride Injection, USP, 40 mg/2 mL (20 mg/mL) single-dose vial by Hospira, Inc. The label shows the vial dosage form, active ingredient strength, and instructions indicating intravenous use only and the need for dilution before use. Additional text includes storage instructions, cautions about the cytotoxic nature of the agent, and barcode information.*
FDA Label Image

Principal Display Panel (5 mL Vial Label)

Principal Display Panel (5 mL Vial Label)
Label for Irinotecan Hydrochloride Injection, USP, 100 mg/5 mL (20 mg/mL) single-dose vial. The label notes it is sterile, for intravenous use only, must be diluted before use, and cautions that it is a cytotoxic agent. The label includes storage instructions, manufacturer Hospira, Inc., and product NDC 61703-349-09 with a barcode.*
FDA Label Image

Principal Display Panel (5 mL Vial Carton)

Principal Display Panel (5 mL Vial Carton)
Packaging label for Irinotecan Hydrochloride Injection, USP, 100 mg/5 mL (20 mg/mL) intravenous solution by Hospira, Inc. The label includes vial depiction, active ingredient details, dilution instructions, storage guidelines, and caution as a cytotoxic agent. Distributed by Hospira, Inc., Lake Forest, IL.*
FDA Label Image

Principal Display Panel (25 mL Vial Label)

Principal Display Panel (25 mL Vial Label)
Label of Irinotecan Hydrochloride Injection, USP, 500 mg per 25 mL (20 mg/mL) single-dose vial for intravenous use. The label notes that the drug must be diluted before use and is a cytotoxic agent. It is distributed by Hospira, Inc., and includes storage instructions, barcode, lot, and expiration placeholders.*
FDA Label Image

Principal Display Panel (25 mL Vial Carton)

Principal Display Panel (25 mL Vial Carton)
Packaging label for Irinotecan Hydrochloride Injection, 500 mg per 25 mL single-dose vial (20 mg/mL) by Hospira, Inc. The label includes dosing instructions, storage conditions, and safety warnings including 'Caution: Cytotoxic Agent'. The product is for intravenous use and must be diluted before use. The vial is sterile and labeled with NDC 61703-349-36.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.